Treatment with trastuzumab, an anti HER-2 antibody, has substantially increased the overall survival rate of patients with HER2-overexpressing cancers; however, trastuzumab resistance develops in most patients within a year [11–13]. This evidence concerns the gene ERBB2 and cancer.